A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label multicenter, phase 1-2 study. Following determination of the
recommended AEG35156 dose in combination with gemcitabine in the initial Phase 1 part of this
study, additional patients will be enrolled in the Phase 2 part of the study to assess the
activity of the combination first-line in advanced pancreatic cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aegera Therapeutics
Treatments:
Gemcitabine X-Linked Inhibitor of Apoptosis Protein